CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant

Drug identity checked against registry records

Also recorded as COVID-19 and influenza combination

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination VaccineNCT06291857NovavaxPhase 3Completed2025-12-24Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.